Abstract
We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients. The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Arthralgia / chemically induced
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Muscles / drug effects
-
Neuromuscular Diseases / chemically induced*
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects*
-
Peripheral Nervous System Diseases / chemically induced
-
Retrospective Studies
Substances
-
Antineoplastic Agents, Phytogenic
-
Paclitaxel